Metformin, Liraglutide and Semaglutide
Antidiabetic drugs used for the purpose of weight loss
DOI:
https://doi.org/10.48017/dj.v8i4.2720Keywords:
Diabetes, Obesity, Slimming, Antidiabetic drugs, Rational use of drugsAbstract
Thepresent study aimed to carry out a bibliographical survey of antidiabetic drugs used for weight loss and their consequences for human health. The drugs most commonly reported in the literature were Metformin, Liraglutide and Semaglutide. The three drugs proved to be effective in weight loss, with Liraglutide having the most pronounced effect, including in clinical studies. Metformin and Semaglutide have been shown to reduce weight, especially when associated with the practice of physical exercise and a change in eating style. However, these drugs have not yet been approved for the purpose of weight loss, and a series of side effects have been reported, mainly associated with the gastrointestinal system, such as nausea, vomiting and diarrhea. Based on the evaluated data, the best way to reduce body weight remains the practice of physical activity and lifestyle changes, and since such practices are not enough, one can opt for the use of anorectics with the proper prescription. and guidance from a health professional. We also highlight the greatest need for the pharmacist, who is responsible for the interface between the drug and the patient, in the education process to avoid the irrational use of antidiabetic drugs in order to lose weight.
Metrics
References
Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P., Birch, S., & Leiter, L. A. (2018). Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 20(9), 2210-2219. https://doi.org/10.1111/dom.13353
Aroda, V. R., Bauer, R., Christiansen, E., Haluzík, M., Kallenbach, K., Montanya, E., Rosenstock, J., & Meier, J. J. (2022). Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes, Obesity and Metabolism, 24(7), 1338-1350. https://doi.org/10.1111/dom.14710
Balaji, R., Duraisamy, R., & Kumar, M. P. (2019). Complications of diabetes mellitus: A review. Drug Invention Today, 12(1).
Cole, J. B., & Florez, J. C. (2020). Genetics of diabetes mellitus and diabetes complications. Nature reviews nephrology, 16(7), 377-390. https://doi.org/10.1038/s41581-020-0278-5
Fonseca, K. P., & Rached, C. D. A. (2019). Complicações do diabetes mellitus. International Journal of Health Management Review, 5(1). https://doi.org/10.37497/ijhmreview.v5i1.149
Freemark, M., & Bursey, D. (2001). The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics, 107(4), e55-e55. https://doi.org/10.1542/peds.107.4.e55
Freitas, G. C. P. L., Vasconcelos, M. C. D. H. V., Bisneta, A. I. S., Parra, R. L. O., Pereira, M. E. B., Negreiros, M. E. L., & Sobrinho, F. E. R. A. (2023). Efeitos do uso de semaglutida como opção farmacológica para o emagrecimento em adultos com IMC> 25 Kg/m²: uma revisão de escopo. Research, Society and Development, 12(4), e9012440955-e9012440955.
Gaia, C. G.; & Souza, N. B. (2018). Eficácia e riscos da utilização da metformina com finalidades diferentes para a qual foi desenvolvida. Faculdade de Atenas, 1(1), 1-18.
Gonçalves, L. S., & Abreu, T. P. (2021). O uso off label de medicamentos para o tratamento da obesidade no Brasil. Revista Ibero-Americana de Humanidades, Ciências e Educação, 7(10), 1165-1177. https://doi.org/10.51891/rease.v7i10.2654
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., & LEAD‐2 and LEAD‐3 Study Groups. (2009). Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity and Metabolism, 11(12), 1163-1172. https://doi.org/10.1111/j.1463-1326.2009.01158.x
Lee, A., & Morley, J. E. (1998). Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non‐insulin‐dependent diabetes. Obesity research, 6(1), 47-53. https://doi.org/10.1002/j.1550-8528.1998.tb00314.x
Lundgren, J. R., Janus, C., Jensen, S. B., Juhl, C. R., Olsen, L. M., Christensen, R. M., & Torekov, S. S. (2021). Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine, 384(18), 1719-1730. doi: 10.1056/NEJMoa2028198
Marques, G. J. R., Luiz, G. G., Neves, J. F., & Castro, L. A. (2021). O uso off label da metformina e fluoxetina para emagrecer e possíveis riscos à saúde. Revista Saúde dos Vales, 1(1) 1-24.
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322. DOI: 10.1056/NEJMoa1603827
Martínez, R., López-Trinidad, L. M., Kapravelou, G., Arrebola, F., Galisteo, M., Aranda, P., & López-Jurado, M. (2020). A combined healthy strategy for successful weight loss, weight maintenance and improvement of hepatic lipid metabolism. The Journal of Nutritional Biochemistry, 85, 108456. https://doi.org/10.1016/j.jnutbio.2020.108456
Mehta, A., Marso, S. P., & Neeland, I. (2017). Liraglutide for weight management: a critical review of the evidence. Obesity science & practice, 3(1), 3-14. https://doi.org/10.1002/osp4.84
Mendes, J. D. O. H., de Cássia Bastos, R., & Moraes, P. M. (2019). Características psicológicas e relações familiares na obesidade infantil: uma revisão sistemática. Revista da Sociedade Brasileira de Psicologia Hospitalar, 22(2), 228-247. https://doi.org/10.57167/Rev-SBPH.22.216
Nilson, E. A. F., Andrade, R. D. C. S., Brito, D. A. D., & Oliveira, M. L. D. (2020). Custos atribuíveis a obesidade, hipertensão e diabetes no Sistema Único de Saúde, Brasil, 2018. Revista Panamericana de Salud Pública, 44, e32.
Nuffer, W. A., & Trujillo, J. M. (2015). Liraglutide: a new option for the treatment of obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 35(10), 926-934. https://doi.org/10.1002/phar.1639
Padhi, S., Nayak, A. K., & Behera, A. (2020). Type II diabetes mellitus: a review on recent drug based therapeutics. Biomedicine & Pharmacotherapy, 131, 110708.
Santos, K.P. et al. Perigo dos medicamentos para emagrecer. Revista de Iniciação Científica e Extensão, v. 2, n. 1, p. 37-45, 2019.
Scott, L. J. (2015). Liraglutide: a review of its use in the management of obesity. Drugs, 75, 899-910. https://doi.org/10.1007/s40265-015-0408-8
Silva, L. F. O. et al. Prevalência do uso de medicamentos para emagrecer entre universitárias. Revista Científica de Enfermagem, v. 3, n. 7, p. 19-26, 2013.
Siqueira, L. O., & Frigeri, F. C. (2018). Uso da metformina como agente emagrecedor. RBONE-Revista Brasileira de Obesidade, Nutrição e Emagrecimento, 12(71), 285-292.
Son, J. W., & Kim, S. (2020). Comprehensive review of current and upcoming anti-obesity drugs. Diabetes & metabolism journal, 44(6), 802-818. doi: https://doi.org/10.4093/dmj.2020.0258
Sousa, D. T. C., Meneses, F. G., Silva, G. L. M., & Cipriano, V. T. F. (2021). Risco do uso indiscriminado de medicamentos para emagrecimento Risk of indiscriminate use of medicines for slimming. Brazilian Journal of Health Review, 4(6), 28589-28602. doi:10.34119/bjhrv4n6-402
Sousa, J. C., Altino, I. P., de Andrade, S. M., Cunha, M. A., de Araújo, B. A. C., & de Oliveira, E. H. (2020). Dieta cetogênica para pacientes com diabetes mellitus tipo II. Research, Society and Development, 9(7), e117973972-e117973972. https://doi.org/10.33448/rsd-v9i7.3972
Srinivasan, S., Ambler, G. R., Baur, L. A., Garnett, S. P., Tepsa, M., Yap, F., ... & Cowell, C. T. (2006). Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. The Journal of Clinical Endocrinology & Metabolism, 91(6), 2074-2080. https://doi.org/10.1210/jc.2006-0241
Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International journal of obesity, 37(11), 1443-1451. https://doi.org/10.1038/ijo.2013.120
Weber, T. P., Bosco, I. E., Barroso, L. M., de Paiva, J. C. M., Passos, X. S., & Antunes, M. J. C. (2023). Uso do medicamento semaglutida como aliado no tratamento da obesidade. Revista Científica Multidisciplinar, 4(2), e422731-e422731. https://doi.org/10.47820/recima21.v4i2.2731
Wilding, J. P. (2018). Medication use for the treatment of diabetes in obese individuals. Diabetologia, 61(2), 265-272. https://doi.org/10.1007/s00125-017-4288-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Sâmia Moreira de Andrade, Maria Victória Macedo de Andrade, Pedro Henrique Almeida de Faria, Luís Marcelo Vieira Rosa, Plínio Robson Cavalcante Costa, Luiz Gustavo Freitas Pires
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Diversitas Journal expresses that the articles are the sole responsibility of the Authors, who are familiar with Brazilian and international legislation.
Articles are peer-reviewed and care should be taken to warn of the possible incidence of plagiarism. However, plagiarism is an indisputable action by the authors.
The violation of copyright is a crime, provided for in article 184 of the Brazilian Penal Code: “Art. 184 Violating copyright and related rights: Penalty - detention, from 3 (three) months to 1 (one) year, or fine. § 1 If the violation consists of total or partial reproduction, for the purpose of direct or indirect profit, by any means or process, of intellectual work, interpretation, performance or phonogram, without the express authorization of the author, the performer, the producer , as the case may be, or whoever represents them: Penalty - imprisonment, from 2 (two) to 4 (four) years, and a fine. ”
.png){kind=logo}
